peptides for hair growth
copper peptides have real follicle biology. nothing here is minoxidil. no peptide on this page has an fda hair-regrowth indication.
copper peptides have real follicle biology and zero fda hair-regrowth indications. ghk-cu drives dermal-papilla proliferation in cell culture, extends anagen in mouse models, and pyo et al. 2007 measured 42.7% reduction in caspase-3 activity in dermal papilla cells (apoptosis protection). a 2023 chinese mouse study using an ionic-liquid microemulsion delivery system reported earlier anagen onset than 5% minoxidil (6 days vs 9). that is the strongest preclinical record any peptide has in this category.
ahk-cu was characterized later in the same pickart copper-peptide program. topical scalp pilot data exists but runs single-group, small-n, and weak compared to minoxidil. cosmetic-grade peptides like snap-8 (acetyl-octapeptide-3) are usually face-wrinkle compounds with sponsor-only data borrowed sideways into hair marketing.
the compounds with real follicle biology.
the cluster with published dermal-papilla cell data, mouse hair-cycle work, and small-scale topical pilots. plasma ghk-cu declines roughly 60% from age 20 to age 60, the original case for topical replacement.
- ghk-cu (tier S) — copper-binding tripeptide. pickart isolated it from human plasma at ucsf in 1973.
- ahk-cu (tier C) — alanine-histidine-lysine copper tripeptide. characterized in the 1990s extension of pickart's copper-peptide program.
- klow (tier C) — four-peptide compounded blend: kpv, ghk-cu, bpc-157, tb-500.
- glow (tier C) — three-peptide blend: bpc-157, ghk-cu, tb-500.
peptides borrowed sideways into hair products.
compounds frequently stacked alongside copper peptides in hair products but whose published data lives in face wrinkles, tissue repair, or vendor literature rather than scalp trials.
- snap-8 (acetyl-octapeptide-3) (tier D) — lipotec acetyl-octapeptide-3. a snap-25 c-terminal mimic that competes with snare-complex assembly to reduce facial-muscle contraction.
- bpc-157 (tier C) — gastric-juice protection fragment with rodent tendon, vascular, and gut-healing data.
- tb-500 (tier C) — 7-amino-acid lkktetq fragment of thymosin-β4.
specific-question reference.
is any peptide fda-approved for hair regrowth?
no. minoxidil (topical, oral) and finasteride are the only drugs with fda hair-loss indications. every peptide in this brief is either cosmetic-grade (ghk-cu, ahk-cu, snap-8) or compounded (klow, glow). none have a phase-3 hair-density rct.
how does ghk-cu compare to minoxidil?
the 2023 chinese mouse study with an ionic-liquid microemulsion vehicle reported earlier anagen entry for topical ghk-cu (6 days) than 5% minoxidil (9 days). that is one preclinical model with engineered delivery. the published human comparison literature is small-n and inconclusive. minoxidil has the long-form efficacy and safety record.
is ahk-cu the same as ghk-cu?
no. both are copper tripeptides from pickart's program. ghk has 50 years of cosmetic and mechanistic literature including the 2014 connectivity-map paper (4,192 genes). ahk-cu has narrower, mostly cosmetic-industry data and one notable 120% dermal-papilla proliferation in vitro reading. they are not evidence-interchangeable.
do glow and klow prove hair regrowth?
no. blend-specific hair-density rcts do not exist. the rationale runs through the ghk-cu component plus general tissue-remodeling extrapolation. that is clinic formulation logic, not phase-3 evidence.
is snap-8 a hair peptide?
no. snap-8 is acetyl-octapeptide-3, a snap-25 c-terminal mimic developed by lipotec for face-wrinkle products. the 63% wrinkle-depth reduction in the sponsor study is at 10% topical on face. scalp use is marketing extension without controlled data.
do bpc-157 or tb-500 belong in a hair-regrowth map?
no. they can be relevant to post-transplant healing because that is a wound question. tendon and vascular biology in rats is not evidence for de novo follicle regrowth in humans.
what the safety literature reports.
what does the topical ghk-cu safety record look like?
ghk-cu has 40+ years of cosmetic use without an adverse-event signal worth tabling. local irritation and contact dermatitis are reported at the same rate as inactive vehicle in pickart-era literature. the safety story is the strongest part of the cosmetic copper-peptide case.
what happens when copper peptides go systemic?
injectable ghk-cu and ahk-cu have a thinner human evidence base than the topical. the cosmetic safety record does not carry across to systemic dosing. no controlled long-term injectable trial in healthy adults.
what is the biggest evidence gap in the category?
controlled human hair-density outcomes for any peptide formula. mouse models and in vitro dermal-papilla work exist. minoxidil-arm controlled human rcts do not.
claim checks
related comparisons
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.